Kymera Therapeutics Inc
KYMR43.020USD
+0.060+0.14%
交易中 （美东）报价延迟15分钟
2.80B总市值
亏损市盈率 TTM
关于 Kymera Therapeutics Inc 公司
Kymera Therapeutics, Inc. 是一家生物制药公司。该公司专注于发现和开发新型小分子疗法，通过利用人体自身的天然蛋白质降解系统选择性地降解致病蛋白质。该公司的靶向蛋白质降解 (TPD) 平台（称为 Pegasus）使其能够发现具有针对全身致病蛋白质活性的高选择性小分子蛋白质降解剂。该公司利用其 Pegasus 平台设计专注于免疫炎症和肿瘤学领域的新型蛋白质降解剂，并继续将其平台的功能应用于其他治疗领域。其临床阶段项目是 IRAK4、STAT3 和 MDM2，它们各自针对生物学上已证实的途径中的高影响目标，为治疗一系列免疫炎症疾病、血液系统恶性肿瘤和/或实体瘤提供了机会。
公司简介
公司代码KYMR
公司名称Kymera Therapeutics Inc
上市日期Aug 21, 2020
CEODr. Nello Mainolfi, Ph.D.
员工数量188
证券类型Ordinary Share
年结日Aug 21
公司地址500 North Beacon Street, 4Th Floor
城市WATERTOWN
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02472
电话18572855314
网址https://www.kymeratx.com/
公司代码KYMR
上市日期Aug 21, 2020
CEODr. Nello Mainolfi, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
659.96K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
67.50K
+23.48%
Mr. Noah Goodman
Mr. Noah Goodman
Chief Business Officer
Chief Business Officer
50.08K
--
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
15.80K
-14.01%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Justine Koenigsberg
Ms. Justine Koenigsberg
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
--
--
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Independent Director
--
--
Mr. Bruce N. Jacobs
Mr. Bruce N. Jacobs
Chief Financial Officer
Chief Financial Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
659.96K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
67.50K
+23.48%
Mr. Noah Goodman
Mr. Noah Goodman
Chief Business Officer
Chief Business Officer
50.08K
--
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
15.80K
-14.01%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Justine Koenigsberg
Ms. Justine Koenigsberg
Vice President - Investor Relations
Vice President - Investor Relations
--
--
收入明细
FY2024
暂无数据
地区USD
名称
营收
占比
United States
47.07M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
Baker Bros. Advisors LP
9.48%
T. Rowe Price Associates, Inc.
9.48%
Avoro Capital Advisors LLC
9.21%
Wellington Management Company, LLP
8.55%
BVF Partners L.P.
7.81%
Other
55.48%
持股股东
持股股东
占比
Baker Bros. Advisors LP
9.48%
T. Rowe Price Associates, Inc.
9.48%
Avoro Capital Advisors LLC
9.21%
Wellington Management Company, LLP
8.55%
BVF Partners L.P.
7.81%
Other
55.48%
股东类型
持股股东
占比
Investment Advisor
40.90%
Investment Advisor/Hedge Fund
31.55%
Hedge Fund
22.61%
Venture Capital
8.27%
Individual Investor
1.40%
Corporation
1.10%
Research Firm
0.91%
Private Equity
0.41%
Bank and Trust
0.39%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
393
75.73M
107.94%
-273.58K
2025Q1
408
74.79M
106.76%
-4.90M
2024Q4
392
73.17M
112.73%
-3.17M
2024Q3
379
71.17M
110.57%
-5.78M
2024Q2
360
69.86M
113.52%
-7.55M
2024Q1
364
70.22M
115.13%
-982.70K
2023Q4
350
63.05M
113.62%
-5.46M
2023Q3
341
59.94M
108.11%
-9.64M
2023Q2
349
61.24M
110.72%
-7.83M
2023Q1
353
62.67M
113.41%
-6.15M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Baker Bros. Advisors LP
6.65M
9.48%
+655.50K
+10.93%
Jun 30, 2025
T. Rowe Price Associates, Inc.
6.65M
9.48%
-169.69K
-2.49%
Mar 31, 2025
Avoro Capital Advisors LLC
6.46M
9.21%
+1.31M
+25.44%
Mar 31, 2025
Wellington Management Company, LLP
6.00M
8.55%
+689.55K
+12.99%
Mar 31, 2025
BVF Partners L.P.
5.48M
7.81%
+317.17K
+6.14%
Jun 30, 2025
The Vanguard Group, Inc.
5.22M
7.45%
+344.08K
+7.05%
Mar 31, 2025
Atlas Venture
4.90M
6.98%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
4.41M
6.28%
-421.36K
-8.72%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.63M
5.17%
-76.67K
-2.07%
Mar 31, 2025
Invus Public Equities Advisors, LLC
3.24M
4.62%
+270.58K
+9.11%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.83%
Harbor Human Capital Factor US Small Cap ETF
0.7%
SPDR S&P Biotech ETF
0.44%
Invesco Nasdaq Biotechnology ETF
0.32%
ProShares Ultra Nasdaq Biotechnology
0.32%
Direxion Daily S&P Biotech Bull 3X Shares
0.25%
First Trust Multi-Manager Small Cap Opportunities ETF
0.25%
T Rowe Price Small-Mid Cap ETF
0.24%
iShares Biotechnology ETF
0.24%
iShares Russell 2000 Growth ETF
0.14%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.83%
Harbor Human Capital Factor US Small Cap ETF
占比0.7%
SPDR S&P Biotech ETF
占比0.44%
Invesco Nasdaq Biotechnology ETF
占比0.32%
ProShares Ultra Nasdaq Biotechnology
占比0.32%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.25%
First Trust Multi-Manager Small Cap Opportunities ETF
占比0.25%
T Rowe Price Small-Mid Cap ETF
占比0.24%
iShares Biotechnology ETF
占比0.24%
iShares Russell 2000 Growth ETF
占比0.14%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
